par Eckert & Ziegler Strahlen- Und Medizintechnik AG (isin : DE0005659700)
Eckert & Ziegler: Changes in the Executive Board and Supervisory Board
EQS-News: Eckert & Ziegler SE / Key word(s): Personnel
Eckert & Ziegler: Changes in the Executive Board and Supervisory Board
03.12.2024 / 14:29 CET/CEST
The issuer is solely responsible for the content of this announcement.
Berlin, 3 December 2024. The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment.
Dr. Mann who holds a doctorate in physics, joined Eckert & Ziegler in 1998 and initially started as head of development. He then served as managing director of various subsidiaries of Eckert & Ziegler SE and was appointed to the Group Executive Committee in 2011. Dr. Mann has proven expertise in the areas of radiation physics, process management and implementation of investment projects.
Jutta Ludwig, whose contract as a member of the Executive Board expires as planned on December 31, 2024 will join the Supervisory Board as a delegated member on January 1, 2025. Frank Perschmann will leave the Supervisory Board of Eckert & Ziegler SE at the end of the year.
“Dr. Mann knows Eckert & Ziegler like only few others and brings exactly the experience and expertise needed to expand production capacity in the growing medical segment and to set up facilities for new products,” explains Dr. Andreas Eckert, Chairman of the Supervisory Board of Eckert & Ziegler SE. “On behalf of the Supervisory Board, I would like to thank Mrs. Ludwig for her contribution in strengthening our position in China and I am pleased that her expertise will remain with the company. I would also like to express my thanks to Mr. Perschmann for his many years of work on the Supervisory Board and for his valuable input in the strategic development of the Group.”
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
03.12.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: | English |
Company: | Eckert & Ziegler SE |
Robert-Rössle-Str.10 | |
13125 Berlin | |
Germany | |
Phone: | +49 30 941084-138 |
Fax: | +49 30 941084-0 |
Internet: | www.ezag.de |
ISIN: | DE0005659700 |
WKN: | 565970 |
Indices: | SDAX, TecDax, |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2043391 |
End of News | EQS News Service |
2043391 03.12.2024 CET/CEST